Anika Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Anika Therapeutics, Inc. (ANIK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.68 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-17.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-03-17
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $3.10M, a 25.23% decline year-over-year.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $3.43M, a 7.72% decline year-over-year.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $3.56M, a 8.13% decline year-over-year.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $4.15M, a 1.69% increase year-over-year.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.68M, a 23.39% decline from fiscal 2023.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $15.24M, a 6.48% increase from fiscal 2022.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.31M, a 29.14% increase from fiscal 2021.
- Anika Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $11.09M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $11.68M 10-K · filed 2025-03-17 | ||||
| 2024-06-30 | $3.10M 10-Q · filed 2024-08-08 | $6.53M derived: sum of 2 quarters · filed 2024-08-08 | |||
| 2024-03-31 | $3.43M 10-Q · filed 2024-08-08 | ||||
| 2023-12-31 | $15.24M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $3.56M 10-Q · filed 2023-11-03 | $7.71M derived: sum of 2 quarters · filed 2024-08-08 | $11.43M derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-06-30 | $4.15M 10-Q · filed 2024-08-08 | $7.87M derived: sum of 2 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $3.72M 10-Q · filed 2024-08-08 | ||||
| 2022-12-31 | $14.31M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $3.88M 10-Q · filed 2023-11-03 | $7.96M derived: sum of 2 quarters · filed 2023-11-03 | $10.50M derived: sum of 3 quarters · filed 2023-11-03 | ||
| 2022-06-30 | $4.08M 10-Q · filed 2023-11-03 | $6.63M derived: sum of 2 quarters · filed 2023-11-03 | |||
| 2022-03-31 | $2.54M 10-Q · filed 2023-11-03 | ||||
| 2021-12-31 | $11.09M 10-K · filed 2024-03-15 | ||||
| 2019-12-31 | $6.09M 10-K · filed 2020-03-06 | ||||
| 2019-09-30 | $1.31M 10-Q · filed 2019-10-28 | $2.75M derived: sum of 2 quarters · filed 2019-10-28 | $4.14M derived: sum of 3 quarters · filed 2020-05-22 | ||
| 2019-06-30 | $1.44M 10-Q · filed 2019-10-28 | $2.83M derived: sum of 2 quarters · filed 2020-05-22 | |||
| 2019-03-31 | $1.39M 10-Q · filed 2020-05-22 | ||||
| 2018-12-31 | $11.05M 10-K · filed 2020-03-06 | ||||
| 2018-09-30 | $1.18M 10-Q · filed 2019-10-28 | $2.50M derived: sum of 2 quarters · filed 2019-10-28 | $10.06M derived: sum of 3 quarters · filed 2019-10-28 | ||
| 2018-06-30 | $1.32M 10-Q · filed 2019-10-28 | $8.89M derived: sum of 2 quarters · filed 2019-10-28 | |||
| 2018-03-31 | $7.57M 10-Q · filed 2019-10-28 | ||||
| 2017-12-31 | $5.81M 10-K · filed 2020-03-06 | ||||
| 2016-12-31 | $3.39M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $2.23M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $1.61M 10-K · filed 2017-02-24 | $1.61M 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $1.27M 10-K · filed 2016-03-10 | $1.27M 10-K · filed 2014-03-13 | |||
| 2012-12-31 | $1.15M 10-K · filed 2015-03-13 | ||||
| 2011-12-31 | $1.19M 10-K · filed 2014-03-13 | ||||
| 2010-12-31 | $1.10M 10-K · filed 2013-03-14 | ||||
| 2009-12-31 | $958.02K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |